Loading...
XKRX
326030
Market cap5.58bUSD
Jul 11, Last price  
98,300.00KRW
1D
-0.71%
1Q
-3.72%
IPO
-40.42%
Name

SK Biopharmaceuticals Co Ltd

Chart & Performance

D1W1MN
P/E
31.98
P/S
14.06
EPS
3,074.04
Div Yield, %
—
Shrs. gr., 5y
32.01%
Rev. gr., 5y
34.62%
Revenues
547.60b
+54.30%
37,631,486,14051,798,062,83060,454,791,13072,440,821,40071,416,701,94089,927,545,43085,316,069,9501,098,738,190123,852,416,02025,999,026,720418,644,529,120246,179,120,020354,891,555,520547,596,283,210
Net income
240.74b
P
-19,465,137,000-30,330,598,000-41,001,914,000-37,048,875,000-28,061,186,000-30,360,843,000-97,649,060,000-138,096,479,000-71,519,466,820-247,413,613,86064,845,640,000-139,430,877,680-32,882,849,240240,738,037,870
CFO
94.90b
P
-16,962,588,800-24,065,043,200-39,064,435,900-40,336,395,590-28,716,692,010-48,941,251,590-98,342,730,340-141,281,399,300-81,334,671,550-210,726,008,610-92,871,732,620-159,920,061,630-94,201,249,07094,899,993,000
Earnings
Aug 06, 2025

Profile

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, discovery, and development of drugs for the treatment of central nervous system disorders. The company is developing Cenobamate for the treatment of epilepsy; Solriamfetol for the treatment of excessive daytime sleepiness in narcolepsy or obstructive sleep apneal; Carisbamate that is in Phase 1b/2 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials to treat rare neurological disease. It is also developing SKL13865 that is in Phase 1 clinical trials to treat attention deficit/hyperactivity disorder; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder; and SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy. The company was founded in 2011 and is headquartered in Seongnam, South Korea. SK Biopharmaceuticals Co., Ltd. operates as subsidiary of SK Inc.
URL
https://www.skbp.com/
IPO date
Jul 02, 2020
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
547,596,283
54.30%
354,891,556
44.16%
246,179,120
-41.20%
Cost of revenue
319,157,510
286,083,665
272,906,388
Unusual Expense (Income)
NOPBT
228,438,773
68,807,890
(26,727,268)
NOPBT Margin
41.72%
19.39%
Operating Taxes
(154,377,679)
(8,478,274)
(3,037,986)
Tax Rate
NOPAT
382,816,452
77,286,164
(23,689,281)
Net income
240,738,038
-832.11%
(32,882,849)
-76.42%
(139,430,878)
-315.02%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
157,805,731
57,060,819
5,644,021
Long-term debt
60,443,576
154,554,982
162,426,161
Deferred revenue
14,761,670
5
31,157,335
Other long-term liabilities
25,112,186
37,702,606
3,198,713
Net debt
(195,997,098)
(133,593,934)
(35,948,162)
Cash flow
Cash from operating activities
94,899,993
(94,201,249)
(159,920,062)
CAPEX
(1,395,344)
(3,249,365)
(5,960,948)
Cash from investing activities
(10,940,813)
225,272,591
(95,713,806)
Cash from financing activities
(4,498,072)
6,622,756
134,914,263
FCF
360,908,594
11,790,307
(46,143,844)
Balance
Cash
324,488,664
241,118,437
305,453,733
Long term investments
89,757,741
104,091,298
(101,435,389)
Excess cash
386,866,591
327,465,157
191,709,387
Stockholders' equity
(554,663,778)
(750,654,664)
(780,103,142)
Invested Capital
1,353,004,036
1,287,358,515
1,286,707,310
ROIC
29.00%
6.00%
ROCE
28.61%
12.78%
EV
Common stock shares outstanding
78,494
78,313
78,313
Price
Market cap
EV
EBITDA
245,866,339
84,125,334
(13,743,530)
EV/EBITDA
Interest
10,682,521
8,279,609
3,716,526
Interest/NOPBT
4.68%
12.03%